Korea's first homegrown obesity drug Eppe reaches prescriptions

Hanmi Pharmaceutical has begun prescribing Eppe (efpeglenatide), South Korea's first domestically developed GLP-1 obesity treatment. A four-week starter supply costs about 129,800 won ($97), roughly half the price of Mounjaro and 40% less than Wegovy. In a Phase 3 trial of 448 Korean patients, average weight loss over 40 weeks was 9.75%.

• Four-week starter course costs 129,800 won ($97) versus about 270,000 won for Mounjaro
• Doses from 2 mg to 10 mg are priced at 24,200 to 74,800 won per pack
• From week 13, a four-week course costs 299,200 won
• First-year sales target is 100 billion won, about 5% of the market